Kezar Life Sciences has hit a roadblock in plans to develop zetomipzomib, its experimental treatment for autoimmune hepatitis (AIH). The company has been unable to reach an agreement with the U.S. Food and Drug Administration (FDA) about plans for a registrational clinical trial — a trial whose data, if positive, could support future applications seeking […] The post Autoimmune hepatitis therapy hits FDA roadblock, future uncertain appeared first on Liver Disease News.
